It has been reported that systemic infusion of AngII or AngII analog increases energy expenditure and reduces WAT mass in rodents.66,67 However, AngII infusion is usually associated with many systemic adverse effects produced by AT1R (for example, hypertension).66 Therefore, direct activation of AT2R by introducing exogenous selective agonists and making endogenous AngII-induced basal AT2R activity more prominent by inhibiting AT1R should be better strategies. This evidence concerns the gene AGTR1 and Hypertension.